神经调控治疗药物难治性神经病理性疼痛的系统综述
本系统综述检索1990至2020年PubMed、Embase和Cochrane Library数据库,评估脊髓电刺激、脑深部电刺激、运动皮层刺激和后岛叶刺激治疗神经病理性疼痛的证据。结果显示MCS、DBS和SCS有较一致证据支持作为可能治疗选择,但无法确定各病因对应的最佳术式,且证据不足以支持常规使用PIS。
要点
- MCS组疼痛改善率35%–80%,DBS组50%–60%,SCS组成功率38%–89%。
- MCS常见病因:幻肢痛和中枢卒中后疼痛;DBS:中枢卒中后疼痛、幻肢痛和脊髓损伤。
- SCS常见病因:复杂区域疼痛综合征和腰椎手术失败综合征。
核心结论
- 有较一致证据支持MCS、DBS和SCS可作为神经病理性疼痛的可能治疗方法。
- 无法确定每种病因应选择哪种术式。
- 证据不足以证明后岛叶刺激的常规使用合理。
研究设计与样本
- 系统综述,检索PubMed、Embase和Cochrane Library数据库1990至2020年文献。
- 纳入提供即时和长期有效性、解剖刺激靶点、疼痛控制百分比和神经病理性疼痛病因数据的研究。
主要发现
- MCS组疼痛改善率在35%至80%之间。
- DBS组疼痛改善率在50%至60%之间。
- SCS组成功率在38%至89%之间。
- MCS组最常见病因为幻肢痛和中枢卒中后疼痛。
- DBS组最常见病因为中枢卒中后疼痛、幻肢痛和脊髓损伤;SCS组为复杂区域疼痛综合征和腰椎手术失败综合征。
关键数值与推荐
- MCS组疼痛改善率35%–80%。
- DBS组疼痛改善率50%–60%。
- SCS组成功率38%–89%。
临床怎么用
- MCS、DBS和SCS可作为药物难治性神经病理性疼痛的神经调控治疗选项。
- 后岛叶刺激证据不足,不应作为常规治疗。
- 术式选择需结合疼痛病因个体化评估,但目前无明确病因对应推荐。
局限性
- 无法确定每种病因应选择哪种刺激术式。
- 后岛叶刺激证据不足。
- 该领域仍有未解决问题,需开展新研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The treatment of neuropathic pain (NP) continues to be controversial as well as an economic health issue and a challenge to health care. Neurosurgery can offer different methods of neuromodulation that may improve patients' condition, including deep brain stimulation (DBS), motor cortex stimulation (MCS), spinal cord stimulation (SCS), and posterior insula stimulation (PIS). There is no consensus of opinion as to the final effects of these procedures, which stimulation parameters to select, the correct timing, or how to select the patients who will best benefit from these procedures. OBJECTIVE: To review the evidence available regarding these 4 procedures and the management of NP. METHODS: We conducted a PubMed, Embase, and Cochrane Library database search from 1990 to 2020. The strategy of the search concentrated on the following keywords: "neuropathic pain," "chronic pain," "deep brain stimulation," "motor cortex stimulation," "spinal cord stimulation," "insula stimulation," and "neuromodulation." Studies that provided data regarding the immediate and long-term effectiveness of the procedure, anatomic stimulation target, percentage of pain control, and cause of the NP were included. RESULTS: The most frequent causes of NP were phantom limb pain and central poststroke pain in the MCS group; central poststroke pain, phantom limb pain, and spinal cord injury (SCI) in the DBS group; and complex regional pain syndrome and failed back surgery syndrome in the SCS group. Pain improvement varied between 35% and 80% in the MCS group and 50% and 60% in the DBS group. In the SCS group, successful rates varied between 38% and 89%. CONCLUSIONS: This systematic review highlights the literature supporting SCS, DBS, MCS, and PIS methods for the treatment of NP. We found consistent evidence supporting MCS, DBS, and SCS as possible treatments for NP; however, we were not able to define which procedure should be indicated for each cause. Furthermore, we did not find enough evidence to justify the routine use of PIS. We conclude that unanswered points need to be discussed in this controversial field and emphasize that new research must be developed to treat patients with NP, to improve their quality of life.
引用
- Galafassi GZ, Simm Pires de Aguiar PH, Simm RF, et al. Neuromodulation for Medically Refractory Neuropathic Pain: Spinal Cord Stimulation, Deep Brain Stimulation, Motor Cortex Stimulation, and Posterior Insula Stimulation. World Neurosurg. 2020. PMID: 33217591. doi:10.1016/j.wneu.2020.11.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。